Symbols

BRNS

Barinthus·NASDAQ

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 2

Ample Liquidity

Significant Revenue Decline

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About BRNS

Barinthus Biotherapeutics Plc

A clinical-stage biopharmaceutical company that develops immunotherapeutcs & vaccines for infectious diseases & cancer

Industry

Biological Technology

Established Date

Listing Date

04/30/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.barinthusbio.com

Security Type

Depository Receipts (Ordinary Shares)

Office address

20400 Century Blvd, Suite 210, Germantown, MD 20874

Business

Introduction

Barinthus Biotherapeutics plc is a public limited company incorporated under the laws of England and Wales in March 2021. The company is a clinical-stage biopharmaceutical company focused on the development of novel immunotherapy candidates for autoimmune and inflammatory diseases. Its lead drug candidate, VTP-1000, utilizes its proprietary SNAP-TI platform to promote immune tolerance in celiac disease, while VTP-300 utilizes viral vector technology to target chronic hepatitis B.

Company Financials

EPS

BRNS has released its 2025 Q4 earnings. EPS was reported at -0.27, versus the expected -0.39, beating expectations. The chart below visualizes how BRNS has performed over recent quarters, highlighting trends in earnings surprises.